Artemis International has announced it has been appointed as the sole distribution partner for innoVactic's InSea2 seaweed-based glucose control ingredient for the US market.
In a statement, the company said the new partnership highlights its strategic expansion beyond its core berry portfolio, enhancing its ability to deliver a more diverse and integrated range of functional ingredients.
Artemis has recently broadened its offerings to include functional mushrooms and a wide array of botanicals.
InSea2 is a natural ingredient derived from sustainably harvested brown seaweeds in the North Atlantic Ocean and manufactured in Canada under strict quality standards.
It is backed by eight clinical trials focused on blood sugar management and metabolic health.
With rising obesity and diabetes rates, the demand for GLP-1 products is increasing.
InSea2 targets two digestive enzymes that convert carbohydrates into glucose, reducing glycemic stress by up to 48.3% from the first use and offering long-term benefits for blood sugar regulation.
Unlike many products that focus solely on weight loss, InSea2 promotes overall metabolic health, which is essential for effective insulin regulation and longevity.
"We are thrilled to begin working with innoVactiv and this amazing ingredient," said Leslie Gallo, President of Artemis International.
We strive to find unique, innovative ingredients that provide natural solutions to health issues and alternatives to pharmaceuticals.
"Blood sugar regulation remains a significant issue for so many and InSea2 has the science showing just how powerful it is in reducing blood sugar spikes and overall metabolic health – one of the keys to longevity."
"This partnership with Artemis is rooted in shared values and common drivers — a strong commitment to science, meaningful differentiation, deep ingredient expertise and a dedication to improving people's well-being," added Patrice Dionne, CEO of innoVactiv.
With 115 million Americans affected by prediabetes, partnering with Artemis enables us to expand access to our science-backed InSea2 and support individuals seeking to maintain healthy blood glucose levels.